Institute of Nuclear Medicine, University College London, London, United Kingdom.
Institute of Nuclear Medicine, University College London, London, United Kingdom; Biomedical Research Centre, University College London Hospital, National Institute for Health Research, London, United Kingdom.
Clin Radiol. 2021 Oct;76(10):784.e1-784.e15. doi: 10.1016/j.crad.2021.08.004.
Positron emission tomography (PET) is an exquisitely sensitive molecular imaging technique with broad utility in cancer diagnosis and monitoring. Many ligands labelled with positron-emitting isotopes have been developed that are of interest in the field of cancer imaging. This review intends to provide an overview and outlook of PET in the field of oncology using radiotracers beyond that of the now widespread 2-deoxy-2-[F]-fluoro-D-glucose (F-FDG). A particular focus is the role of PET in understanding and monitoring the tumour microenvironment (TME) in response to chemo-radiotherapy. Furthermore priority will be given to aspects where PET has provided for monitoring of the immune response to cancer including the expanding field of cancer immunotherapy and in the arena of theranostics. The development of new techniques from both preclinical and human studies will be included to give a perspective on future directions, thereby helping to illustrate the importance of PET in cancer patient management.
正电子发射断层扫描(PET)是一种极其灵敏的分子成像技术,在癌症诊断和监测方面具有广泛的应用。已经开发出许多用正电子发射同位素标记的配体,这些配体在癌症成像领域具有重要意义。本综述旨在概述和展望使用超越广泛应用的 2-脱氧-2-[F]-氟-D-葡萄糖(F-FDG)的放射性示踪剂在肿瘤学领域的 PET,重点关注 PET 在理解和监测肿瘤微环境(TME)对化放疗反应的作用。此外,将优先考虑 PET 在监测癌症免疫反应方面提供的信息,包括癌症免疫治疗领域的扩展和治疗学领域。将纳入来自临床前和人体研究的新技术发展,以展望未来方向,从而有助于说明 PET 在癌症患者管理中的重要性。